Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide

Circulation Journal

Volumn 71, Issue 5, 2007, Pages 716-721

  Nakahara, Takao ^a   Takata, Yoshifumi ^a   Hirayama, Yoji ^a   Asano, Kihiro ^a   Adachi, Hirotaka ^a   Shiokawa, Genzo ^a   Sumi, Teijin ^a   Ogawa, Takashi ^a   Yamashina, Akira ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Essential hypertension; Left ventricular geometry; Left ventricular hypertrophy; Procollagen type III amino terminal peptide

Indexed keywords

ALDOSTERONE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; GEOMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

ALDOSTERONE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 34247602146     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.716     Document Type: Article

References (44)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: The Framingham Heart Study. Ann Intern Med 1989; 110: 101-107.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
3. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31: 1635-1640.
4. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879-884.
5. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
6. Morgan HE, Baker KM. Cardiac hypertrophy mechanical, neural, and endocrine dependence. Circulation 1991; 83: 13-25.
7. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990; 65: 1-7.
8. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
9. Young M, Fullerton M, Dilley R, Funder JW. Mineralcorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583.
10. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 2000; 25: 299-306.
11. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12-16.
12. Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y. Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res 2002; 25: 49-56.
13. Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K. Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens 1995; 13: 155-160.
14. Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J 1998; 135: 58-66.
15. Soylu A, Temizhan A, Duzenli MA, Sokmen G, Koylu O, Telli HH. The influence of aldosterone on the development of left ventricular geometry and hypertrophy in patients with essential hypertension. Jpn Heart J 2004; 45: 807-821.
16. Trinchet JC, Hartmann DJ, Pateron D, Laarif M, Callard P, Ville G, et al. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis: Relationship to liver histology and conventional liver tests. J Hepatol 1991; 12: 139-144.
17. Low RB, Cutroneo KR, Davis GS, Giancola MS. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest 1983; 48: 755-759.
18. Horslev-Petersen K, Bentsen K, Junker P, Lorenzen I. Serum aminoterminal type III procollagen peptide in rheumatoid arthritis. Arthritis Rheum 1986; 29: 592-599.
19. Keller F, Rehbein C, Scwarz A, Fleck M, Hayasaka A, Schuppan D, et al. Increased procollagen III production in patient with kidney disease. Nephron 1988; 50: 332-337.
20. Weber KT. Cardiac interstitium in health and disease: The fibrillar collagen network. J Am Coll Cardiol 1989; 13: 1637-1652.
21. Bonnet J, Garderes PE, Aumailley N, Moreau C, Gouverneur G, Benchimol D, et al. Serum type III procollagen peptide levels in coronary artery disease (a marker of atherosclerosis). Eur J Clin Invest 1988; 18: 18-21.
22. Jensen LT, Petersen KH, Toft P, Bentsen KD, Grande P, Simonsen EE, et al. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation 1990; 81: 52-57.
23. Robert V, Thiem NV, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994; 24: 30-36.
24. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26: 971-978.
25. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222-1230.
26. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55: 613-618.
27. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J 3rd, et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham study. Circulation 1987; 75: 26-33.
28. Vasan RS, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41.
29. Yamamoto N, Yasue H, Mizuno Y, Yoshimura M, Fujii H, Nakayama M, et al. Aldosterone is produced from ventricules in patients with essential hypertension. Hypertension 2002; 39: 958-962.
30. Mizuno Y, Yasue H, Yoshimura M, Hararda E, Fujii H, Nakamura S, et al. Adrenocorticotropic hormone is produced in the ventricle of patients with essential hypertension. J Hypertens 2005; 23: 411-416.
31. Bauwens FR, Duprez DA, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1991; 68: 925-929.
32. Navarro-Lopez F, Coca A, Pare JC, De La Sierra A, Bosch X, Urbano Marquez A. Left ventricular hypertrophy in asymptomatic essential hypertension: Its relationship with aldosterone and the increase in sodium-proton exchanger activity. Eur Heart J 1993; 14(Suppl J): 38-41.
33. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, et al. Left ventricular hypertrophy is more prominent in patient with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 1997; 20: 85-90.
34. Matoba M, Asaji T, Matsui S, Takekoshi N. Long-term effect of delapril hydrochloride on procollagen type III amino-terminal peptide, left ventricular mass and left ventricular function in hypertensive patients. Jpn Circ J 1998; 62: 900-902.
35. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837-842.
36. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 838-844.
37. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al for the Randomized Aldactone Evaluation study. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
38. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000; 102: 2700-2706.
39. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, et al. Effect of spironolactone during an angiotensin II recepter blocker treatment on the lef ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 2006; 70: 995-1000.
40. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Circ Res 1991; 69: 107-115.
41. Fagard RH, Lijnen PJ, Petrov VV. Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. J Hum Hypertens 1998; 12: 195-202.
42. Hollander W. Role of hypertension in atherosclerosis and cardiovascular disease. Am J Cardiol 1976; 23: 786-800.
43. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558.
44. Conrady AO, Rudomanov OG, Zaharov DV, Iakovleva OI, Ovchinnicova OA, Vahrameeva NV, et al. Prospective study of the changes in left ventricular mass and geometry patterns in hypertensive patients during 5 years of follow-up. Circ J 2005; 69: 1374-1379.